(NASDAQ: OTLK) Outlook Therapeutics's forecast annual revenue growth rate of 487.09% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.38%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.35%.
Outlook Therapeutics's revenue in 2026 is $205,702.On average, 5 Wall Street analysts forecast OTLK's revenue for 2026 to be $1,797,657,059, with the lowest OTLK revenue forecast at $702,333,091, and the highest OTLK revenue forecast at $4,014,055,822. On average, 5 Wall Street analysts forecast OTLK's revenue for 2027 to be $4,911,679,878, with the lowest OTLK revenue forecast at $1,324,091,009, and the highest OTLK revenue forecast at $11,569,598,223.
In 2028, OTLK is forecast to generate $1,934,884,057 in revenue, with the lowest revenue forecast at $1,858,960,645 and the highest revenue forecast at $1,991,785,082.